REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -1.13

EPS: As of FY2025 Q1, the actual value is USD -1.13.

Segment Revenue

• Research and Development Expenses: $205.7 million for the three months ended March 31, 2025, compared to $118.0 million for the same period in 2024, representing a 74% increase.
• General and Administrative Expenses: $35.0 million for the three months ended March 31, 2025, compared to $22.8 million for the same period in 2024, representing a 53% increase.

Operational Metrics

• Net Loss: $213.4 million for the three months ended March 31, 2025, compared to $116.0 million for the same period in 2024.
• Loss from Operations: $240.8 million for the three months ended March 31, 2025, compared to $140.9 million for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $194.4 million for the three months ended March 31, 2025, compared to - $160.6 million for the same period in 2024.
• Net Cash Used in Investing Activities: - $15.9 million for the three months ended March 31, 2025, compared to - $248.0 million for the same period in 2024.
• Net Cash Provided by Financing Activities: $0.9 million for the three months ended March 31, 2025, compared to $0.8 million for the same period in 2024.

Unique Metrics

• Stock-Based Compensation Expense: $25.1 million for the three months ended March 31, 2025, compared to $16.2 million for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: Revolution Medicines, Inc. plans to advance its RAS(ON) inhibitors, including daraxonrasib, elironrasib, and zoldonrasib, through clinical development with ongoing and planned Phase 3 trials. The company expects to initiate pivotal combination studies in 2026.
• Non-Core Business: The company is exploring collaborations, such as with Aethon Therapeutics, Inc. and Tango Therapeutics, Inc., to enhance its research and development efforts.